Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Figure-of-Eight Suture and Perclose ProGlide Suture-Mediated Closure in Large Bore Venous Access Hemostasis: A Randomized Controlled Trial.

The American journal of cardiology·2023
Same author

Percutaneous Left Atrial Appendage Closure Among Patients With Diabetes (Insights from a National Database).

The American journal of cardiology·2023
Same author

Coronary Obstruction From TAVR in Native Aortic Stenosis: Development and Validation of Multivariate Prediction Model.

JACC. Cardiovascular interventions·2023
Same author

Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion.

Heart rhythm O2·2022
Same author

Transvalvular Pressure Gradients and All-Cause Mortality Following TAVR: A Multicenter Echocardiographic and Invasive Registry.

JACC. Cardiovascular interventions·2022
Same author

Decline in the Volume of Structural Heart Procedures in the United States Due to the COVID-19 Pandemic.

Structural heart : the journal of the Heart Team·2022

Related Experiment Video

Updated: Jul 8, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

10.5K

Transcatheter aortic-valve replacement with a self-expanding prosthesis.

David H Adams1, Jeffrey J Popma, Michael J Reardon

  • 1From Mount Sinai Medical Center, New York (D.H.A.), and St. Francis Hospital, Roslyn (N.R., G.P.) - both in New York; Beth Israel Deaconess Medical Center, Boston (J.J.P.); Houston Methodist DeBakey Heart and Vascular Center (M.J.R., N.S.K.), and Texas Heart Institute at St. Luke's Medical Center (J.S.C.) - both in Houston; Riverside Methodist Hospital, Columbus, OH (S.J.Y.); University of Michigan Medical Center, Ann Arbor (G.M.D., S. Chetcuti), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; University of Pittsburgh Medical Center, Pittsburgh (T.G.G.); Palo Alto Veterans Affairs Medical Center, Palo Alto, CA (M.B.); St. Vincent Medical Center, Indianapolis (J.H.); University of Kansas Hospital, Kansas City (G.Z., P.T.); Duke University Medical Center, Durham, NC (G.C.H., J.K.H.); Johns Hopkins Hospital, Baltimore (J.C.); Pinnacle Health, Harrisburg, PA (B.M., M.M.); and Medtronic, Minneapolis (S. Chenoweth), and Mayo Clinical Foundation, Rochester (J.K.O.) - both in Minnesota.

The New England Journal of Medicine
|April 1, 2014
PubMed
Summary

Transcatheter aortic-valve replacement (TAVR) showed improved survival rates compared to traditional surgery for severe aortic stenosis patients at high surgical risk. This finding offers a less invasive option for high-risk individuals needing aortic valve replacement.

More Related Videos

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.7K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

720

Related Experiment Videos

Last Updated: Jul 8, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

10.5K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.7K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

720

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Severe aortic stenosis poses significant risks, especially for patients with increased surgical mortality.
  • Transcatheter aortic-valve replacement (TAVR) emerged as an alternative to surgical aortic-valve replacement (SAVR).
  • This study focused on high-risk patients where the benefits of TAVR over SAVR were less clear.

Purpose of the Study:

  • To compare the efficacy and safety of TAVR versus SAVR in patients with severe aortic stenosis and high surgical risk.
  • To evaluate the primary endpoint of all-cause mortality at one year post-procedure.
  • To assess noninferiority and superiority of TAVR compared to SAVR.

Main Methods:

  • A randomized controlled trial involving 795 patients with severe aortic stenosis and high surgical risk.
  • Patients were assigned 1:1 to receive either TAVR with a self-expanding bioprosthesis or SAVR.
  • The primary endpoint was the rate of death from any cause at 1 year, analyzed using both noninferiority and superiority testing.

Main Results:

  • TAVR demonstrated a significantly lower rate of all-cause mortality at 1 year (14.2%) compared to SAVR (19.1%) in the as-treated analysis.
  • The absolute risk reduction for mortality with TAVR was 4.9 percentage points, meeting both noninferiority (P<0.001) and superiority (P=0.04) criteria.
  • TAVR was also noninferior in echocardiographic valve function, functional status, and quality of life, with exploratory analyses suggesting fewer adverse cardiovascular events.

Conclusions:

  • For patients with severe aortic stenosis at high surgical risk, TAVR using a self-expanding bioprosthesis is associated with significantly higher survival rates at one year compared to SAVR.
  • TAVR represents a viable and potentially life-saving alternative for this high-risk patient population.
  • The study provides strong evidence supporting the use of TAVR in selected high-risk patients with severe aortic stenosis.